Adagene Inc. (ADAG), Tuesday announced strategic investment of upto $25 million and option exercise by Sanofi (SNY).
As per the deal, Adagene will supply Sanofi with muzastotug to evaluate the safety, efficacy, pharmacokinetics and biomarker data in combination with other anticancer therapies in over 100 patients in a phase 1/2 clinical trial in advanced solid tumors.
Additionally, Sanofi has also exercised its option to select a third SAFEbody discovery program, utilizing Adagene's proprietary masking technology and antibody engineering expertise.
The biotechnology company intends to use the proceeds for funding purposes, including clinical development of muzastotug, an anti-CTLA-4 SAFEbody, through a randomized phase 2 trial in microsatellite stable colorectal cancer.
Notably, the proceeds from Sanofi along withe existing cash and cash equivalents, are expected to be sufficient to fund planned operations into 2027.
In the pre-market hours, ADAG is climbing 9.74 percent, to $2.14 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.